Transcranial Temporal Interference Stimulation (tTIS) for Chronic Insomnia
An Exploratory Randomized Controlled Clinical Trial of Transcranial Temporal Interference Stimulation (tTIS) for the Treatment of Chronic Insomnia
The purpose of this exploratory randomized controlled clinical trial is to evaluate the efficacy and safety of transcranial temporal interference stimulation (tTIS) in the treatment of chronic insomnia. The study aims to investigate whether non-invasive tTIS intervention can effectively modulate specific neural activities to improve sleep quality and alleviate related clinical symptoms in patients suffering from chronic insomnia.
Participants enrolled in this study will be randomly assigned to receive either active tTIS treatment or sham stimulation. Researchers will collect clinical assessments and sleep monitoring data before, during, and after the intervention to compare the outcomes between the different groups and determine the therapeutic potential of tTIS for insomnia management.
Visão geral do estudo
Status
Condições
Descrição detalhada
Background and Rationale:
Chronic insomnia involves not only difficulty initiating sleep but also continuous central hyperarousal, severely impairing daytime function and quality of life. Current sedative-hypnotic drugs typically provide only nighttime suppression of the central nervous system, which can lead to tolerance and next-day residual effects, and they fail to fundamentally restore normal brain network states. There is a clinical need for non-invasive neuromodulation targeting abnormal brain networks. The left dorsolateral prefrontal cortex (DLPFC) is implicated in regulating emotion and suppressing central hyperarousal. Transcranial temporal interference stimulation (tTIS) is a novel non-invasive technique that uses two high-frequency carriers to create a modulated envelope (e.g., 10Hz) at a specific cortical target. The 10Hz modulation is hypothesized to modulate alpha activity, potentially reducing cortical hyperarousal. This study will evaluate the clinical safety and preliminary efficacy of tTIS targeting the left DLPFC, and will test whether it is associated with network-level changes in insomnia patients.
Study Objective:
The primary objective is to evaluate the preliminary clinical efficacy of tTIS targeting the left DLPFC in treating chronic insomnia, utilizing the reduction rate of the Insomnia Severity Index (ISI) score as the primary endpoint. Secondary objectives include evaluating the clinical response rate and objective sleep structural changes via polysomnography (PSG) and sleep bands. The study will also explore the neurophysiological mechanisms by analyzing electroencephalogram (EEG) Alpha band power. Additionally, it will assess improvements in subjective arousal (PSAS) and emotional states (STAI-S, PHQ-9, GAD-7).
Study Design and Methodology:
This is a prospective, single-center, randomized, double-blind (participant and evaluator), sham-controlled exploratory clinical trial. Thirty eligible patients with primary or mild emotionally accompanied chronic insomnia will be enrolled and randomly assigned to either the experimental group (10Hz difference frequency tTIS) or the control group (0Hz difference frequency tTIS) in a 1:1 ratio. The study location is Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.
Intervention Details:
Both groups will receive stimulation targeting the left DLPFC. The experimental group will receive 10Hz difference frequency tTIS (carrier frequencies of 2000Hz and 2010Hz), which creates an amplitude-modulated envelope. The control group will receive 0Hz difference frequency stimulation (identical carrier frequencies), which does not create a therapeutic modulated envelope. The intervention will be administered daily for 30 minutes per session, 5 times a week, over a continuous 2-week period (10 sessions in total). Follow-up assessments will cover the baseline, the end of the intervention, and one month post-intervention.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Yan Luo, MD, PhD
- Número de telefone: 666225 0086-021-64370045
- E-mail: zhy12015@rjh.com.cn
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Aged 18 to 65 years old, male or female.
- Eligibility required an ICD-11 diagnosis of chronic insomnia disorder, determined by investigator-administered clinical interviews (≥3 nights/week for ≥3 months, despite adequate opportunity/conditions for sleep, with daytime distress or functional impairment).
- Insomnia Severity Index (ISI) total score ≥ 15 at screening or baseline assessment.
- Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) total scores both ≤ 9 at screening assessment.
- Has full civil capacity, is able to proficiently operate a smartphone and wearable sleep band, and can understand and cooperate with clinical scale assessments and neurophysiological examinations.
- Voluntarily participates, can ensure on-time hospital visits for 10 transcranial temporal interference stimulation (tTIS) sessions over 2 consecutive weeks, and can cooperate with the 1-month longitudinal follow-up.
- Fully understands the study purpose, intervention procedures, and potential risks, and voluntarily signs the written informed consent form.
Exclusion Criteria:
- Psychiatric conditions: (1) schizophrenia spectrum disorder or bipolar disorder, determined based on participant self-report of prior clinician diagnosis and treatment history and, when feasible, review of available medical records; (2) moderate-to-severe depressive or anxiety symptoms (PHQ-9 ≥ 10 or GAD-7 ≥ 10; either threshold met); (3) current suicidal ideation/behavior or elevated suicide risk as assessed by the investigator.
- Secondary sleep disorders: Severe obstructive sleep apnea (OSA; AHI ≥ 30), restless legs syndrome (RLS), narcolepsy, or severe circadian rhythm disorders.
- Epilepsy risk: History of seizures/convulsions or a clear family history of epilepsy.
- Intracranial metal and implanted electronic devices: Intracranial metal implants (e.g., aneurysm clips, metal stents, repair patches; fixed dental fillings excluded) or implanted electronic devices (e.g., cardiac pacemakers, deep brain stimulators [DBS], vagus nerve stimulators [VNS]).
- Medical history (neurologic): Recent craniotomy, severe traumatic brain injury, or organic brain lesions (e.g., brain tumors).
- Special populations: Pregnant, lactating, or planning pregnancy during the study period.
- Skin and physical restrictions: Skin damage, infection, or severe rash at the scalp stimulation site (especially over the left DLPFC and the return electrode site), or severe allergy to conductive gel/electrodes.
- Somatic comorbidities/substance use: Severe cardiac, pulmonary, hepatic, or renal dysfunction, or other conditions deemed by the investigator to potentially affect participant safety or study assessments (e.g., severe alcohol or drug abuse).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Experimental Group: 10Hz tTIS
Participants in this group will receive active 10Hz difference frequency tTIS targeting the left dorsolateral prefrontal cortex (DLPFC).
The intervention will be administered for 30 minutes per session, 5 times a week, over a continuous 2-week period (10 sessions in total)
|
Utilizing the NeuroDome TES NEURO-800 device to deliver active tTIS targeting the left dorsolateral prefrontal cortex (DLPFC).
The stimulation uses carrier frequencies of 2000Hz and 2010Hz to generate a 10Hz amplitude-modulated envelope at the target region.
Each session lasts for 30 minutes.
|
|
Comparador Falso: Sham Comparator: 0Hz tTIS
Participants in this group will receive 0Hz difference frequency tTIS (sham stimulation) targeting the left DLPFC.
The intervention frequency and duration are identical to the experimental group: 30 minutes per session, 5 times a week, for 2 weeks (10 sessions in total).
|
Utilizing the NeuroDome TES NEURO-800 device to deliver sham tTIS targeting the left dorsolateral prefrontal cortex (DLPFC).
The stimulation uses carrier frequencies of 2000Hz and 2000Hz to generate a 0Hz amplitude-modulated envelope at the target region.
Each session lasts for 30 minutes.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Insomnia Severity Index (ISI) Score
Prazo: Baseline (Day 1) and within 24 hours (0-24 h) after completion of the final treatment session on Day 13.
|
The Insomnia Severity Index (ISI) is a validated 7-item self-report questionnaire used to assess the nature, severity, and impact of insomnia.
The total score ranges from 0 to 28, with higher scores indicating more severe insomnia symptoms.
The primary endpoint is the change from baseline in ISI total score at End of Intervention, calculated as ISI (Baseline) minus ISI (End of Intervention).
Positive values indicate improvement.
|
Baseline (Day 1) and within 24 hours (0-24 h) after completion of the final treatment session on Day 13.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Insomnia Severity Index (ISI) Response Rate
Prazo: Baseline (Day 1) and within 24 hours (0-24 h) after completion of the final treatment session on Day 13.
|
ISI response is defined as a decrease of ≥6 points in the ISI total score from baseline to post-treatment.
Participants will be classified as responders if their ISI total score decreases by ≥6 points from baseline (Day 1) to the post-treatment assessment completed within 24 hours (0-24 h) after completion of the final treatment session (Day 13).
The response rate will be calculated as the proportion of responders in each group (n/N, %).
|
Baseline (Day 1) and within 24 hours (0-24 h) after completion of the final treatment session on Day 13.
|
|
Insomnia Severity Index (ISI) Remission Rate
Prazo: Baseline (Day 1) and within 24 hours (0-24 h) after completion of the final treatment session on Day 13.
|
ISI remission is defined as a post-treatment ISI total score <8 points.
Participants will be classified as in remission if their ISI total score is <8 points at the post-treatment assessment completed within 24 hours (0-24 h) after completion of the final treatment session (Day 13).
The remission rate will be calculated as the proportion of participants meeting this criterion in each group (n/N, %).
|
Baseline (Day 1) and within 24 hours (0-24 h) after completion of the final treatment session on Day 13.
|
|
Change from baseline in Pittsburgh Sleep Quality Index (PSQI) total score
Prazo: Baseline (Day 1); within 24 hours (0-24 h) after completion of the final treatment session on Day 13; and end of follow-up on Day 44.
|
Pittsburgh Sleep Quality Index (PSQI) total score (range 0-21; higher scores indicate worse sleep quality).
Change from baseline will be calculated as baseline minus post-treatment and baseline minus end-of-follow-up; positive values indicate improvement (i.e., a reduction in PSQI total score).
|
Baseline (Day 1); within 24 hours (0-24 h) after completion of the final treatment session on Day 13; and end of follow-up on Day 44.
|
|
Pre-Sleep Arousal Scale (PSAS) score
Prazo: Baseline (Day 1); within 24 hours (0-24 h) after completion of the final treatment session on Day 13; and end of follow-up on Day 44.
|
PSAS score (range: 18-80; higher scores indicate greater pre-sleep arousal).
Change from baseline will be calculated as baseline minus post-treatment and baseline minus end-of-follow-up; positive values indicate improvement (i.e., a reduction in PSAS score).
|
Baseline (Day 1); within 24 hours (0-24 h) after completion of the final treatment session on Day 13; and end of follow-up on Day 44.
|
|
State-Trait Anxiety Inventory-State (STAI-S) total score
Prazo: Baseline (Day 1); within 24 hours (0-24 h) after completion of the final treatment session on Day 13 and end of follow-up on Day 44.
|
STAI-S total score (range: 20 to 80; higher scores indicate greater state anxiety).
Change from baseline will be calculated as baseline minus post-treatment; positive values indicate improvement (i.e., a reduction in STAI-S total score).
|
Baseline (Day 1); within 24 hours (0-24 h) after completion of the final treatment session on Day 13 and end of follow-up on Day 44.
|
|
Patient Health Questionnaire-9 (PHQ-9) total score
Prazo: Baseline (Day 1); within 24 hours (0-24 h) after completion of the final treatment session on Day 13; and end of follow-up on Day 44.
|
PHQ-9 total score (range: 0 to 27; higher scores indicate worse depressive symptoms).
Change from baseline will be calculated as baseline minus post-treatment and baseline minus end-of-follow-up; positive values indicate improvement (i.e., a reduction in PHQ-9 total score).
|
Baseline (Day 1); within 24 hours (0-24 h) after completion of the final treatment session on Day 13; and end of follow-up on Day 44.
|
|
Generalized Anxiety Disorder-7 (GAD-7) total score
Prazo: Baseline (Day 1); within 24 hours (0-24 h) after completion of the final treatment session on Day 13; and end of follow-up on Day 44.
|
GAD-7 total score (range: 0 to 21; higher scores indicate worse anxiety symptoms).
Change from baseline will be calculated as baseline minus post-treatment and baseline minus end-of-follow-up; positive values indicate improvement (i.e., a reduction in GAD-7 total score).
|
Baseline (Day 1); within 24 hours (0-24 h) after completion of the final treatment session on Day 13; and end of follow-up on Day 44.
|
|
Total sleep time (TST) by polysomnography (PSG)
Prazo: Overnight on Day 1 and overnight on Day 13.
|
Total sleep time (TST) measured by overnight polysomnography (PSG), in minutes.
TST is defined as the total time scored as sleep during the PSG recording.
Change from baseline will be calculated as post-treatment minus baseline.
|
Overnight on Day 1 and overnight on Day 13.
|
|
Sleep onset latency (SOL) by polysomnography (PSG)
Prazo: Overnight on Day 1 and overnight on Day 13.
|
Sleep onset latency (SOL) measured by overnight PSG, in minutes.
SOL is defined as the time from lights out to sleep onset per standard PSG scoring.
Change from baseline will be calculated as baseline minus post-treatment (positive values indicate shorter SOL).
|
Overnight on Day 1 and overnight on Day 13.
|
|
N1 sleep percentage (N1%) by polysomnography (PSG)
Prazo: Overnight on Day 1 and overnight on Day 13.
|
Percentage of total sleep time spent in stage N1 sleep (N1%), measured by overnight PSG (0-100%).
Change from baseline will be calculated as post-treatment minus baseline (percentage points).
|
Overnight on Day 1 and overnight on Day 13.
|
|
N2 sleep percentage (N2%) by polysomnography (PSG)
Prazo: Overnight on Day 1 and overnight on Day 13.
|
Percentage of total sleep time spent in stage N2 sleep (N2%), measured by overnight PSG (0-100%).
Change from baseline will be calculated as post-treatment minus baseline (percentage points).
|
Overnight on Day 1 and overnight on Day 13.
|
|
N3 sleep percentage (N3%) by polysomnography (PSG)
Prazo: Overnight on Day 1 and overnight on Day 13.
|
Percentage of total sleep time spent in stage N3 sleep (N3%), measured by overnight PSG (0-100%).
Change from baseline will be calculated as post-treatment minus baseline (percentage points).
|
Overnight on Day 1 and overnight on Day 13.
|
|
REM sleep percentage (REM%) by polysomnography (PSG)
Prazo: Overnight on Day 1 and overnight on Day 13.
|
Percentage of total sleep time spent in REM sleep (REM%), measured by overnight PSG (0-100%).
Change from baseline will be calculated as post-treatment minus baseline (percentage points).
|
Overnight on Day 1 and overnight on Day 13.
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Wearable-estimated light sleep proportion (HUAWEI Band 10)
Prazo: Day 1 through Day 44.
|
Proportion of sleep time classified as "light sleep" by the HUAWEI Band 10 using the manufacturer's proprietary algorithm.
Values will be derived from wearable device records during the monitoring period.
|
Day 1 through Day 44.
|
|
Wearable-estimated deep sleep proportion (HUAWEI Band 10)
Prazo: Day 1 through Day 44.
|
Proportion of sleep time classified as "deep sleep" by the HUAWEI Band 10 using the manufacturer's proprietary algorithm.
Values will be derived from wearable device records during the monitoring period.
|
Day 1 through Day 44.
|
|
Wearable-estimated REM sleep proportion (HUAWEI Band 10)
Prazo: Day 1 through Day 44.
|
Proportion of sleep time classified as "REM sleep" by the HUAWEI Band 10 using the manufacturer's proprietary algorithm.
Values will be derived from wearable device records during the monitoring period.
|
Day 1 through Day 44.
|
|
Heart rate variability (HRV) from wearable device (HUAWEI Band 10)
Prazo: Day 1 through Day 44.
|
Heart rate variability (HRV) measured by the HUAWEI Band 10 and calculated using the manufacturer's proprietary algorithm.
HRV metrics will be derived from wearable device records during the monitoring period.
|
Day 1 through Day 44.
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- (2026)Lin Lun Shen No.(466)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .